SNGLR Capital
Exponential tech focused Venture Capital Fund We invest in mainly European early-stage technology Start-ups (Seed) with exponential growth potential in the sectors: longevity / vitality and smart mobility / city; enabled by these technologies: AI, Blockchain, Data (IoT; API), 5G, Robotics and others. We work with entrepreneurs through all ups and downs on your journey as one team: - experience as founders, early-stage tech investors, board members, advisors, mentors and coaches - special engagement model with selected Corporate Venture Units and Consulting Firms with strong market access - technology insights and support provided by our XLabs tech dev gurus
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.